The $6.5bn price – biopharma’s biggest buyout of the year so far – shows how competitive the anti-FcRn space has become.
Crucial clinical data are expected in the third quarter for small to mid-sized players including Beigene, Turning Point, Intra-cellular and Immunovant.
A new mechanism for certain autoimmune conditions takes a big step forward with impressive pivotal data on Argenx’s efgartigimod.
After a delay Wave will finally see data for its Huntington's disease projects while Argenx's subcutaneous efgartigimod needs to keep the competition at bay.
The company plans to make the most of its head start with the Graves’ disease project teprotumumab, which is forecast to become its biggest product.